行情

SGEN

SGEN

西雅图遗传学
NASDAQ

实时行情|Nasdaq Last Sale

169.03
+1.51
+0.90%
盘后: 169.03 0 0.00% 18:11 07/02 EDT
开盘
167.75
昨收
167.52
最高
170.36
最低
166.02
成交量
78.29万
成交额
--
52周最高
175.64
52周最低
63.02
市值
292.59亿
市盈率(TTM)
-90.6716
分时
5日
1月
3月
1年
5年

分析师评级

20位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测SGEN价格均价为165.35,最高价位251.00,最低价为95.00。

EPS

SGEN 新闻

更多
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The busy calendar of June proved positive for drug approvals, with most scheduled events producing positive outcomes. New molecular entity, or NME, approval for the month totaled two, taking the total NME approvals for the year to 24.
Benzinga · 2天前
Kiniksa's Heart Drug, And Other News: The Good, Bad, And Ugly Of Biopharma
Seeking Alpha - Article · 3天前
Oppenheimer Maintains Outperform on Seattle Genetics, Raises Price Target to $210
Oppenheimer maintains Seattle Genetics (NASDAQ:SGEN) with a Outperform and raises the price target from $200 to $210.
Benzinga · 3天前
The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test
Benzinga · 3天前
The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29)
Benzinga · 3天前
SVB Leerink Maintains Outperform on Seattle Genetics, Raises Price Target to $167
SVB Leerink analyst Andrew Berens maintains Seattle Genetics (NASDAQ:SGEN) with a Outperform and raises the price target from $155 to $167.
Benzinga · 3天前
Needham Maintains Buy on Seattle Genetics, Raises Price Target to $188
Needham analyst Chad Messer maintains Seattle Genetics (NASDAQ:SGEN) with a Buy and raises the price target from $163 to $188.
Benzinga · 3天前
Seattle Genetics Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
Business Wire · 4天前

所属板块

生物技术和医学研究
+0.68%
制药与医学研究
+0.61%

热门股票

代码
价格
涨跌幅

SGEN 简况

Seattle Genetics, Inc.是一家从事癌症治疗方法的开发和商业化的生物技术公司。其产品ADCETRIS(brentuximab vedotin)是抗体-药物偶联物(ADC)。ADCETRIS包含通过可分离蛋白酶连接到微管抑制剂monomethyl auristatin E(MMAE)上的抗CD30单克隆抗体。 该公司也提供其他临床级ADC,包括SGN-CD33A、SGN-CD19A、SGN-LIV1A、SGN-CD70A、ASG-22ME、ASG-15ME和SEA-CD40(基于sugar-engineered antibody 技术)。SGN-CD33A是用于治疗急性骨髓性白血病(AML)的ADC(由抗CD33单克隆抗体组成)。SGN-CD19A是用于治疗恶性血液病的ADC(由抗CD19单克隆抗体组成)。SGN-LIV1A是用于治疗LIV-1-positive转移性乳腺癌的ADC(由抗LIV-1单克隆抗体组成)。
展开

微牛提供Seattle Genetics, Inc.(NASDAQ-SGEN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的SGEN股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易SGEN股票基本功能。